Abstract:Background: Chemotherapy is currently one of the most common/important treatments for cancers; however the occurrence of multidrug resistance (MDR) impedes the successful application of chemotherapeutic agents. The active efflux of anti-cancer drugs through multi-drug resistance protein 1 (MRP1) remains the dominant mechanism of MDR. However, mechanisms underlying the MRP1 upregulation during tumorigenesis and chemotherapy remain elusive. Methods: MRP1 expression, the efflux probability and viability were measured to evaluate MDR of human lung cancer A549/DDP and H1299 cells. Pharmacological treatment, shRNA-based konckdown and rescue were used to assess the function of JNK (c-Jun N-terminal kinase) and Sp1 (stimulatory phosphatase 1). Chromatin immunoprecipitation and dual-luciferase reporter assay were used to test the direct binding and activation of MRP1 promotor by Sp1. Findings: Pharmacological analysis and JNK knockdown revealed the direct modulation of MRP1 expression and MDR by by the JNK signaling pathway. Furthermore, the transcript factor Sp1 downstream of JNK showed close association with MRP1 expression and MDR. Chromatin immunoprecipitation and luciferase assays revealed the direct binding and activation of MRP1 promoter by Sp1, while Sp1 knockdown decreased MRP1 expression and reversed MDR. Importantly, the MRP1 upregulation and MDR mediated by JNK activation were substantially abolished by Sp1 knockdown in both A549/DDP and H1299 cells. Interpretation: This work demonstrates that Sp1 is a critical transcription factor for MRP1 downstream of JNK and plays a key role in MRP1 upregulation and MDR during tumorigenesis and chemotherapy. Targeting Sp1 expression/activation sheds new light on the clinical chemotherapy treatments of cancers.Funding Statement: This work was supported by the National Natural Science Foundation of China (31400708 and 31670843), the Natural Science Foundation of Heilongjiang Province, China (C200624, C201241, and C201453), the Shaanxi Natural Science Funds for Distinguished Young Scholars of China (2019JC-07), the Key Research and Development Program of Shaanxi Province, China (2017SF-113), and the Fundamental Research Funds for the Central Universities (2017qngz10).Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: Not required.

Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer

Research Progress on Relationship Between Transcription Factor Sp1 and Tumor

Sp1-Mediated Transcriptional Regulation of Malat1 Plays A Critical Role in Tumor

Sp1-CD147 positive feedback loop promotes the invasion ability of ovarian cancer.

Expression of CD147 in Advanced Non-Small Cell Lung Cancer Correlated with Cisplatin-Based Chemotherapy Resistance.

Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma

SP1 is required for basal activation and chromatin accessibility of CD151 promoter in liver cancer cells.

SP1 Mediates MRP1 Upregulation and Multi-Drug Resistance in Human Lung Cancer Cells

Sp1 and the ‘hallmarks of cancer’

SP1 Mediates LMCD1-AS1/let-7b-5p Axis to Promote Epithelial-Mesenchymal Transition of Lung Cancer Cells

System Analysis of the Regulation of the Immune Response by CD147 and FOXC1 in Cancer Cell Lines

A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis

SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression

[Highly Expressed CD147 on CD4⁺ Tumor Infiltrating Lymphocytes Promotes the Progress of Breast Cancer].

Altered Expression of Transcription Factor Sp1 Critically Impacts the Angiogenic Phenotype of Human Gastric Cancer

A Regulatory Loop Involving Mir-29C and Sp1 Elevates the TGF-β1 Mediated Epithelial-to-mesenchymal Transition in Lung Cancer.

Transcription Factor Specifidty Protein 1: a New Biomarker for Pancreatic Cancer Therapy

Role of post-translational modifications of Sp1 in cancer: state of the art

Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors.

Pan-cancer analysis of Sp1 with a focus on immunomodulatory roles in gastric cancer

Transcriptional Regulation of BNIP3 by Sp3 in Prostate Cancer